Fig.7
From: CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
Longitudinal observation of TNF-α and trastuzumab on HER2 + breast cancer. Human recombinant TNF-α and trastuzumab was used to determine if decreased cell viability in co-cultured groups is the result of TNF-α receptor activation in conjunction with trastuzumab induced HER2 receptor blockade in a BT474 and c SKBR3 cell lines. Two HER2 + cell lines were used and both cell lines had similar responses in cancer cells treated with human recombinant TNF-α and trastuzumab vs trastuzumab treated cancer cells co-cultured with T-cells in b BT474 and d SKBR3 cell lines (p = 0.01 and 0.33, respectively)